K12 Vs M18 Probiotic Lozenges: How Brands Choose A Named Strain for OEM Development

TAKEAWAYS

• K12 and M18 are named strain routes, not two labels for the same active: request the complete strain designation, identity method, authorized source, and evidence file before artwork or quotation.

• A probiotic lozenge and a probiotic chewable are different delivery briefs: dissolution time, saliva exposure, bite force, flavor release, and unit-dose expectations must be defined before a formula is selected.

• One incoming-material CFU result does not approve a retail product: the commercial specification needs identity and viable-count controls at receiving, finished-product release, and the agreed expiry point in the actual pack.

• Taste is a technical approval gate: strain powder, carrier matrix, sweetener system, acidulants, and flavor can create dairy, fermented, sulfurous, bitter, or powdery notes that a generic mint flavor does not automatically hide.

• Protected-strain naming requires supply and claim controls: confirm the authorized route, territory, permitted naming, and target-market label review before a brand prints K12, M18, or a clinical-study reference.

Concept manufacturing visual. Replace with a Qiaoerna first-party R&D or QC photograph when available.

1. Start With a Non-Brushing Product Job, Not a Species Name

Start with the intended use moment, then select a named strain and format to match it. A lozenge is a dissolution experience; a chewable is portable. Neither should be positioned as a medical product without the applicable development and review route.

ISAPP distinguishes a general “contains probiotics” statement from claims needing further substantiation.[1] For OEM buying, a generic “oral probiotic blend” is not enough to approve formula copy or packaging.

Problem 1: the brief asks for an “oral probiotic” but does not state the format or use occasion

A supplier cannot set taste, dissolution, packaging, or viable-count checkpoints from a vague microbiome concept. “Daily lozenge after lunch” and “portable chewable for travel” are different briefs.

Buyer action: Put the format, serving form, target use occasion, target market, named strain, sensory direction, and desired retail pack on separate lines before requesting samples.

2. Compare K12 and M18 as Separate Commercial Candidates

K12 and M18 are separately identified Streptococcus salivarius strains; a shared species name does not make their evidence, commercial permissions, or finished-product requirements interchangeable.

An in-vitro co-culture study reported K12 and M18 inhibition and lower volatile-sulfur-compound release under laboratory conditions.[4] This is a technical hypothesis, not a finished-lozenge result or consumer claim. An M18 persistence study found dose-dependent, person-variable persistence after 28 days.[5] It is not a universal dosage or colonisation promise.

3. Do Not Treat “Other Oral Probiotics” as Commodity Substitutes

An alternative strain is a valid candidate only when it is named, documented, and supported for the proposed non-brushing format. A high CFU number, a familiar gut species, or a low price does not establish suitability.

EFSA considered a specific Limosilactobacillus reuteri strain pair in orodispersible lozenges sufficiently characterised, yet found the submitted evidence insufficient for the proposed normal-gum-function relationship.[6] A characterised ingredient and a permitted finished-product claim are separate decisions.

Shortlist a strain only after the supplier provides:

1. Full genus, species, and strain designation.

2. Lot-level identity and viable-count method and unit.

3. Evidence relevant to the proposed format.

4. Market-appropriate safety, naming, formula, and pack-validation documents.

Concept manufacturing visual. It illustrates document review, not a test result or a strain claim.

4. Choose Between a Slow-Dissolve Lozenge and a Chewable Before Formula Approval

A lozenge is a controlled-dissolution format; a chewable is a short-use, bite-driven format. Do not assume the same culture produces the same sensory or viable-count profile in both.

A delivery-carrier review identifies viability, adhesion, delivery site, and carrier choice as separate design considerations.[7]

Problem 2: a pleasant prototype is approved before its use profile is defined

A chewable may win a first tasting yet fail its intended use; a lozenge may dissolve correctly but feel chalky. Buyer action: define “one lozenge,” “one chewable,” or another precise use statement before setting sample criteria.

5. Build the Sensory System Around the Culture, Not Around a Generic Mint Flavor

Live-culture powders and their carriers can introduce notes that must be screened in the finished unit. Assess fermented, dairy-like, sulfurous, bitter, acidic, dry, or powdery perceptions alongside the intended flavor.

Screen the same named strain across the intended sweetener, acidulant, flavor, and carrier system. Assess first taste, mid-use experience, finish, and aftertaste; do not assume a flavor masks every culture note.

6. Define Viable Count as an End-of-Shelf-Life Finished-Product Control

The useful commercial number is the agreed viable count in the finished serving at the end of shelf life—not only a raw-powder count at receiving. There is no universal CFU target. Set the specification using strain-specific evidence, intended serving, market review, and final-pack stability data.

Use three checkpoints in the quality agreement:

1. Incoming material: strain identity, supplier lot, test method, viable-count basis, storage condition, and remaining shelf life.

2. Finished-product release: viable count per serving or gram, recovery method, sample plan, formula version, and batch identity.

3. Stability to expiry: agreed timepoints and conditions in the exact blister, sachet, jar, tube, or other proposed retail pack.

The M18 compositional guideline illustrates how identity, protective matrix, and viable plate-count method can appear in an incoming-material specification.[3] It does not prove that a finished lozenge or chewable meets its own shelf-life target.

Concept manufacturing visual. Replace with a Qiaoerna first-party QC photograph where available.

7. Match Packaging to Moisture Risk and Consumer Use

The package is part of the viability plan, not a final artwork decision. Moisture, oxygen, repeated opening, and handling risks differ between a blister, sachet, and multi-unit jar.

Problem 3: the culture is approved, but the consumer pack is not

A pilot in a laboratory container does not validate a retail pack. The stability plan must name the actual pack, closure, storage assumptions, and sample identity.

Buyer action: Do not sign off a sample without a written pack version. Treat a packaging-material or closure change as a change-control event requiring a documented risk review.

8. Control Supply Rights, Identity, and Claims Before Artwork

A named strain is a formulation and commercial-control choice. If a brief or pack uses a protected strain name, confirm the authorized source, product scope, territory, and permitted naming. BLIS presents K12 and M18 as IP-protected strains.[2]

Use this pre-artwork gate:

• Sourcing: written confirmation of the authorized route, product scope, territory, and permitted naming.

• Identity: supplier documents naming the exact strain and method used to identify or count it.

• Viability: a clear end-of-shelf-life specification for the final serving and retail pack.

• Claims: target-market review separating scientific context from finished-product language.

• Continuity: storage limits, material-change notification, and an agreed change-control route.

For U.S. foods and dietary supplements, FDA distinguishes health claims, nutrient-content claims, and structure/function claims.[8] Final classification and wording require target-market review; a “clinically studied strain” reference does not support disease-related language for a new product.

9. Approve a Strain-Ready Sample, Not Just a Good-Tasting Sample

The approval sample should show the complete commercial system—not only a pleasant flavor. Through its customized oral-care service, Qiaoerna can structure a named-strain brief, format discussion, packaging selection, sampling, and documentation requests. See the oral lozenge and breath-mint category and the Qiaoerna Knowledge library for product-line and technical-article context, not proof that every strain is compatible.

Before a purchase order, request the final strain designation, source, formula and pack version, sensory criteria, test method, release criteria, stability status, label review, and traceability route.

Bottom line: Choose K12, M18, or another candidate only when identity, supply rights, non-brushing format, sensory profile, final-pack viability, and claim boundary form one documented system. For an evidence-led oral-probiotic OEM brief, provide the target market, format, and exact strain.

Frequently Asked Questions

Is K12 the same as M18?

No. They are separately identified Streptococcus salivarius strains. Review their evidence, supplier route, permitted naming, and non-brushing finished-product compatibility separately. A common species name does not transfer a claim or study result.

Can an OEM use K12 or M18 without an authorized supplier?

Do not assume it can. Both are commercially presented as IP-protected. Confirm the authorized source, written permissions, territory, naming terms, and documents before formula approval or artwork.

What CFU should an oral probiotic lozenge contain?

There is no universal amount. Set the target using strain-specific evidence, serving size, market review, and finished-product stability data. Define the viable count at release and through expiry in the quality agreement.

Is a probiotic lozenge better than a chewable?

They answer different product jobs. A lozenge is designed for a controlled dissolution experience, while a chewable is bite-driven and shorter in use. Choose the use occasion first, then test the named strain in that exact format and pack.

Can a brand use a generic “oral probiotic blend” claim?

That is a weak technical brief. The product file should identify the strain, supplier, viable-count method, evidence source, and expiry-date plan. Proposed wording still requires target-market review.

What should a probiotic lozenge sample COA include?

Request the strain designation, supplier lot, test method, viable count and unit, test date, storage condition, expiry or retest date, formula version, pack version, test-sample location, and acceptance criterion.

How is this page different from Qiaoerna’s probiotic toothpaste-tablet article?

That existing page covers K12/M18 in a brushing-format toothpaste tablet, including compression and water-free formulation questions. This page addresses non-brushing lozenges and chewables: strain selection, sensory approval, unit-dose format, retail-pack stability, and documentation before OEM sampling.

References

1. Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11:506–514. https://doi.org/10.1038/nrgastro.2014.66

2. BLIS Technologies. Private Label Probiotics. Supplier information; accessed 2026-10-14. https://blis.co.nz/private-label/

3. Therapeutic Goods Administration. Compositional Guideline for Streptococcus salivarius M18. https://www.tga.gov.au/sites/default/files/compositional-guideline-streptococcus-salivarius-m18.pdf

4. Park J-A, Lee GR, Lee J-Y, Jin B-H. Oral probiotics, Streptococcus salivarius K12 and M18, suppress the release of volatile sulfur compounds and a virulent protease from oral bacteria: an in-vitro study. Oral Health & Preventive Dentistry. 2023;21:b4328987. https://doi.org/10.3290/j.ohpd.b4328987

5. Burton JP, Wescombe PA, Macklaim JM, et al. Persistence of the oral probiotic Streptococcus salivarius M18 is dose dependent and megaplasmid transfer can augment their bacteriocin production and adhesion characteristics. PLOS ONE. 2013;8(6):e65991. https://doi.org/10.1371/journal.pone.0065991

6. EFSA NDA Panel. Orodispersible lozenges containing a combination of Lactobacillus reuteri DSM 17938 and L. reuteri ATCC PTA 5289 and maintenance of normal gum function: evaluation of a health claim. EFSA Journal. 2020;18(3):6004. https://doi.org/10.2903/j.efsa.2020.6004

7. How Y-H, Yeo S-K. Oral probiotic and its delivery carriers to improve oral health: a review. Microbiology. 2021;167(8):001076. https://doi.org/10.1099/mic.0.001076

8. U.S. Food and Drug Administration. Label Claims for Food & Dietary Supplements. Updated 2024-03-28. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/label-claims-food-dietary-supplements